The content on this website is only for individuals that have been prescribed NEXTSTELLIS in Australia.

IMPORTANT SAFETY INFORMATION FOR NEXTSTELLIS® (estetrol/drospirenone tablets) 

▼  This medicine is new and is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you may experience to your doctor, or directly at www.tga.gov.au/reporting-problems

References

1. Gemzell-Danielsson K, et al. Estetrol-Drospirenone combination oral contraceptive: a clinical study of contraceptive efficacy, bleeding pattern and safety in Europe and Russia. BJOG. 2022; 129: 63-71. 2. NEXTSTELLIS Product Information. 3. NEXTSTELLIS Consumer Medicine Information. 4. Stanczyk FZ, et al. Ethinyl estradiol and 17β-estradiol in combined oral contraceptives: pharmacokinetics, pharmacodynamics and risk assessment. Contraception. 2013;87(6):706-727.

The following content is for Australian patients who have been prescribed this product. To access the content, please insert only the numbers that appear after the letters AUST R as printed on the product's pack

AUST R
  Back to Top